Do omega-3s work better for inflamed depression?
In this open trial, patients with an hs-CRP of 1 mg/L or above improved more on the depression scale after eight weeks of add-on omega-3 than patients below that threshold. A cut-off of 3 mg/L did not separate responders from non-responders.
All 101 patients received the same supplement on top of their existing antidepressant. The comparison here is between patients grouped by their baseline inflammation, not between an omega-3 group and a placebo group.
What the data show:
- hs-CRP at or above 1 mg/L: associated with greater improvement in HAMD-17 total score
- hs-CRP at or above 3 mg/L: not associated with greater improvement
- Symptom detail: in patients above the 1 mg/L threshold, added EPA improved fatigue and sleep difficulties
- Dose: 2.2 g EPA, 400 mg DHA and 800 mg of other fatty acids daily for eight weeks
- Blinding: patients and raters did not know baseline hs-CRP status
The trial, published in Brain, Behavior, and Immunity, sorted patients by one biomarker: high-sensitivity C-reactive protein. Every participant took the supplement, and the researchers asked whether baseline hs-CRP predicted who improved.
Dr. Kumar’s Take
The design here is the interesting part. Blinding both patients and raters to baseline hs-CRP status removes an obvious source of bias: if you know a patient is in the “inflamed” group you expect them to do better, and expectation leaks into a rating scale. That the 1 mg/L cut-off separated the groups while 3 mg/L did not is worth sitting with, because 3 mg/L is the threshold most clinicians reach for. It suggests the relevant signal is at a lower level of inflammation than the one I habitually use, or that the cut-off is unstable in a sample this size.
I would not change practice on this. There is still no biomarker of antidepressant treatment response in clinical use, and the authors say so plainly. What this trial does is add to a body of work suggesting that sorting depression by inflammation may eventually be clinically useful. The fatigue and sleep findings interest me most, because those are the symptoms that track with inflammation in the first place, and they are the ones patients complain about longest.
Study Snapshot
All subjects received 2.2 g EPA, 400 mg docosahexaenoic acid and 800 mg of other fatty acids daily for eight weeks, added on to stable ongoing antidepressant treatment. The primary outcome was change in the 17-item Hamilton Depression Rating Scale, HAMD-17. Patients and raters were blind to baseline hs-CRP status. The analysis reported here was intention-to-treat, including all subjects with at least one post-baseline visit, n = 101.
The hypothesis under test was that add-on EPA has greater antidepressant efficacy in patients with major depressive disorder who have high baseline hs-CRP compared with patients who have low hs-CRP.
Results in Real Numbers
An hs-CRP cut-off of 1 mg/L or above was associated with a greater improvement in HAMD-17 total score. A cut-off of 3 mg/L or above was not.
Beyond the general antidepressant effect seen in patients with hs-CRP at or above 1 mg/L, adjuvant EPA improved symptoms the authors describe as putatively related to inflamed depression: fatigue and sleep difficulties.
The authors position the result as adding to mounting evidence that dividing major depressive disorder into subgroups based on inflammation may be clinically relevant for predicting response to anti-inflammatory interventions. They also state that despite decades of research, no biomarkers of treatment response have been clinically implemented.
Who Benefits Most
On the evidence from this trial, the group that improved more was patients with major depressive disorder whose baseline hs-CRP was 1 mg/L or above, taking omega-3 on top of an antidepressant they were already on and stable with.
The trial does not tell you whether omega-3 outperforms placebo in either group, because there was no placebo arm. It tells you that among people taking it, the ones with higher baseline hs-CRP improved more on HAMD-17, and that their fatigue and sleep difficulties improved.
Safety, Limits, and Caveats
The main structural limit is the absence of a placebo comparison. Everyone received the supplement, so improvement over eight weeks cannot be separated from the natural course of the illness, the ongoing antidepressant, or expectation. The comparison the trial supports is between inflammation strata, not between treatment and no treatment.
The two cut-offs disagreed. A threshold of 1 mg/L predicted greater improvement and 3 mg/L did not, which is the kind of result that needs replication before anyone builds a treatment decision on it. Everyone was also on stable antidepressant treatment already, so this speaks to omega-3 as an add-on and not as a first-line treatment on its own. And the authors are explicit that no biomarker of treatment response has made it into clinical practice.
Practical Takeaways
- This trial studied omega-3 added to an antidepressant a patient was already taking and stable on, not omega-3 by itself
- The threshold that separated better responders was an hs-CRP of 1 mg/L or above, a lower bar than the 3 mg/L figure often used for cardiovascular risk
- An hs-CRP of 3 mg/L or above did not identify greater improvement in this trial
- Fatigue and sleep difficulties were the specific symptoms that improved in patients above the 1 mg/L threshold
- Biomarker-guided selection of antidepressant treatment is not established practice, and this trial does not make it so
What This Means for Depression Treatment
Clinical and biological heterogeneity among patients with major depressive disorder is one reason progress in this field has been slow, and it is the problem this trial is trying to address. Depression with low-grade inflammation, described here as inflamed depression, is proposed as a subtype that may respond better to anti-inflammatory compounds. EPA has anti-inflammatory properties, which is the rationale for testing it in this group.
This trial is one contribution to that argument. It supports the idea that sorting patients by inflammation may predict who responds to an anti-inflammatory intervention, and it leaves the question of clinical implementation open.
Related Studies and Research
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
Inflamed Depression: Interactions Between Depression and Inflammation
FAQs
What is “inflamed depression”?
The authors use the term for major depressive disorder with low-grade inflammation, a proposed subtype that may respond better to anti-inflammatory compounds.
What did patients actually take?
2.2 g EPA, 400 mg docosahexaenoic acid and 800 mg of other fatty acids daily for eight weeks, added to antidepressant treatment they were already on and stable with.
Which inflammatory marker did the study use?
Patients were sorted by high-sensitivity C-reactive protein. A cut-off of 1 mg/L or above was associated with greater improvement in HAMD-17. A cut-off of 3 mg/L or above was not.
Can my doctor use a blood test to pick my antidepressant?
Not at present. The authors state that no biomarkers of treatment response have been clinically implemented.
Bottom Line
In 101 patients taking add-on omega-3 alongside their existing antidepressant, a baseline hs-CRP of 1 mg/L or above was associated with greater improvement on HAMD-17 over eight weeks, and with improvement in fatigue and sleep difficulties. A 3 mg/L cut-off was not. This adds to the evidence that inflammation may help define depression subgroups, and it does not yet give anyone a test to guide treatment.
